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See related research by Kang et al., http://arthritis-research.com/content/15/6/R194In a recent report in Arthritis Research & Therapy, Kang
and colleagues [1] assessed a series of patients with
rheumatoid arthritis (RA) to establish whether adipo-
kines could be a link between inflammation, insulin re-
sistance, and atherosclerosis in RA.
We have noticed that Kang and colleagues did not pay
attention to our former studies on the same issue. In this
regard, in the last decade, we conducted a series of stud-
ies on insulin resistance and adipokines in a cohort of
Spanish patients with long-standing RA, undergoing
anti-tumor necrosis factor-alpha (anti-TNF-α) infliximab
therapy because of severe disease, refractory to conven-
tional disease-modifying anti-rheumatic drugs [2-6].
Kang and colleagues described that resistin was associ-
ated with erythrocyte sedimentation rate (ESR) (r = 0.322,
P <0.001), C-reactive protein (CRP) (r = 0.209, P = 0.004),
and increased disease duration (r = 0.176, P = 0.014) [1].
These data are not new. We previously reported a close
association between laboratory markers of inflammation,
particularly CRP and resistin levels [3]. In our series,
we found a significant association between the mean ESR
(r = 0.405, P = 0.03) and CRP (r = 0.571, P = 0.0005) from
disease diagnosis and ESR (r = 0.486, P = 0.004), CRP (r =
0.599, P = 0.0005), and platelet count (r = 0.559, P =
0.0007) at the time of the study and resistin levels [3].
These findings, along with these new data described by
Kang and colleagues, highlight the potential role of resistin
in the inflammatory cascade in RA.
Kang and colleagues also found a positive correlation
between adiponectin and ESR (r = 0.162, P = 0.025) [1].
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observed that high-grade inflammation was independ-
ently and negatively correlated with circulating adipo-
nectin concentrations [4]. CRP levels correlated with
circulating adiponectin concentrations (partial r (pr) =
−0.370, P = 0.04), independently of age and gender [4].
In contrast, low adiponectin levels clustered with meta-
bolic syndrome features that contribute to atherogenesis
in RA [4]. Adiponectin concentrations correlated with
triglycerides/high-density lipoprotein (HDL) cholesterol
ratios (pr = −0.396, P = 0.03), total cholesterol/HDL chol-
esterol ratios (pr = −0.444, P = 0.01), and high fasting
plasma glucose levels (pr = −0.366, P = 0.04), independ-
ently of CRP levels and the body mass index [4]. These
results also suggest an implication of adiponectin in the
development of cardiovascular disease in RA.
In the series by Kang and colleagues, leptin was associ-
ated with homeostasis model assessment-estimated insu-
lin resistance (r = 0.369, P <0.001) [1]. In our series of
RA patients with active disease despite anti-TNF-α ther-
apy, there was a positive correlation between body mass
index of RA patients and serum leptin levels (r = 0.665,
P <0.001) [5]. Also, a significant correlation of leptin
with biomarkers of endothelial activation (vascular cell
adhesion molecule-1; r = 0.349, P = 0.04) was observed
[5]. However, no significant correlations between leptin
levels and disease duration, ESR and CRP levels, disease
activity score using 28 joint counts, lipids, insulin sensi-
tivity, resistin, adiponectin, or the cumulative prednisone
dose at the time of the study were found [5]. Therefore,
in Western patients with severe and active RA, leptin
levels seem to be related to adiposity [5]. However, in
our series, circulating visfatin levels were unrelated to
disease activity, adiposity, or metabolic syndrome [6].
Although adipokines have been demonstrated to exert
a key role in the interface between obesity, inflamma-
tion, insulin resistance, and atherosclerosis in the general
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http://arthritis-research.com/content/16/1/401population, we agree with Kang and colleagues that in-
formation on their potential contribution is still limited
in RA. In this regard, in Western individuals with RA,
adipokines have not been demonstrated to represent a
significant risk factor for indirect measures of organic
arterial wall atherosclerotic damage, as assessed by ca-
rotid intima-media thickness in our cohort of long-
standing active RA patients undergoing infliximab treat-
ment [7], or by coronary artery calcification evaluation,
as shown in recent work by Rho and colleagues [8].
Abbreviations
anti-TNF-α: Anti-tumor necrosis factor-alpha; CRP: C-reactive protein;
ESR: Erythrocyte sedimentation rate; HDL: High-density lipoprotein;
RA: Rheumatoid arthritis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MAG-G made substantial contributions to conception and design of the
manuscript, helped to draft the manuscript, and has given final approval of
the version to be published. RL-M, CG-J, and JL helped in the design of the
manuscript and drafted the manuscript. All authors have read and approved
the final manuscript.
Acknowledgments
The studies on rheumatoid arthritis by the MAG-G group were supported by
‘Fondo de Investigaciones Sanitarias’ grants PI06/0024, PS09/00748, and PI12/
00060 (Spain). This work was also partially supported by RETICS Programs
RD08/0075 (RIER) and RD12/0009/0013 from the ‘Instituto de Salud Carlos III’
(ISCIII) (Spain). RL-M is a recipient of a Sara Borrell postdoctoral fellowship
from the Instituto Carlos III de Salud at the Spanish Ministry of Health (Spain).
Author details
1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic
Inflammatory Diseases, Rheumatology Division, Hospital Universitario
Marqués de Valdecilla, IFIMAV, Avenida de Valdecilla s/n, 29008 Santander,
Spain. 2Division of Cardiology, Hospital Universitario Lucus Augusti, Calle San
Cibrao s/n, 27003 Lugo, Spain. 3Division of Epidemiology and Computational
Biology, School of Medicine, University of Cantabria, Santander, Spain. 4CIBER
Epidemiología y Salud Pública (CIBERESP), IFIMAV, Avenida Cardenal Herrera
Oria s/n, 29011 Santander, Spain.
Published:
References
1. Kang Y, Park HJ, Kang MI, Lee HS, Lee SW, Lee SK, Park YB: Adipokines,
inflammation, insulin resistance, and carotid atherosclerosis in patients
with rheumatoid arthritis. Arthritis Res Ther 2013, 15:R194.
2. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C,
Sanchez-Andrade A, Martin J, Llorca J: Anti-tumor necrosis factor-alpha
blockade improves insulin resistance in patients with rheumatoid
arthritis. Clin Exp Rheumatol 2006, 24:83–86.
3. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy
JA, Vazquez-Rodriguez TR, De Matias JM, Martin J, Dessein PH, Llorca J:
Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid
arthritis. Clin Exp Rheumatol 2008, 26:311–316.
4. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De
Matias JM, Martin J, Redelinghuys M, Woodiwiss AJ, Norton GR, Dessein PH:
High-grade inflammation, circulating adiponectin concentrations and
cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp
Rheumatol 2008, 26:596–603.
5. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C,
Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH,
Llorca J: Anti-TNF-alpha therapy does not modulate leptin in patients
with severe rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:222–228.
10 Feb 20146. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, Berja A,
Miranda-Filloy JA, de Matias JM, Gonzalez-Juanatey C, Llorca J: Visfatin is
not associated with inflammation or metabolic syndrome in patients
with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin
Exp Rheumatol 2010, 28:56–62.
7. Gonzalez-Gay MA, Gonzalez-Juanatey C, Rodriguez-Rodriguez L,
Miranda-Filloy JA, Martin J, Llorca J: Lack of association between
adipokines and ghrelin and carotid intima-media thickness in patients
with severe rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:358–359.
8. Rho YH, Chung CP, Solus JF, Raggi P, Oeser A, Gebretsadik T, Shintani A,
Stein CM: Adipocytokines, insulin resistance, and coronary atherosclerosis
in rheumatoid arthritis. Arthritis Rheum 2010, 62:1259–1264.
Cite this article as: Gonzalez-Gay et al.: Response to ‘Adipokines,
inflammation, insulin resistance, and carotid atherosclerosis in patients
with rheumatoid arthritis’. Arthritis Research & Therapy
10.1186/ar4478
2014, 16:401
